Kallikrein system during treatment of hematological malignancies.
Factors of the plasma kallikrein system have been evaluated following the course of 48 patients with hematological malignancies which consisted of 15 cases of AML, 6 cases of myeloproliferative disorders, 14 of lymphoproliferative disorders, 8 of multiple myeloma and 5 of bone marrow carcinomatoses. Normal range of spontaneous activity was 11.4 +/- 3.0 micronM/ml TAMe hydrolyzed, kallikreinogen was 115.8 +/- 26.2 micronM/ml.h and enzyme inhibitor was 1.02 +/- 0.37 unit. Lower kallikreinogen level of the range was from 77.2 to 93.1; higher spontaneous activity, 8.4 to 18.0 and lower enzyme inhibitor activity of 0.46 to 0.92 was seen before treatment. Kallikreinogen increased up to the range of 95.6 to 120.1 at complete remission and decreased down to 63.1 - 76.5 prior to death. The causes of the change in these factors were discussed.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology; D008223:Lymphoma / Q000201:enzymology; D009101:Multiple Myeloma / Q000201:enzymology; D009369:Neoplasms / Q000201:enzymology*
D000970:Antineoplastic Agents; D007610:Kallikreins